Showing results (61-70 of 92) with videos related to
Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.Lung Cancer (Amsterdam, Netherlands)|January 3, 2024
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancerByoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, et al.Investigational New Drugs|March 9, 2023
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 studyJames Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, et al.The Oncologist|December 20, 2019
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine CarcinomasMing-Huang Chen, Wen-Chi Chou, Chin-Fu Hsiao, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in TaiwanYuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.Lung Cancer (Amsterdam, Netherlands)|March 5, 2023
Proliferative ability of circulating tumor cells is a prognostic factor in Early-Stage lung adenocarcinomaTing-Fang Che, Chao-Hua Chiu, Yu-Chung Wu, et al.Japanese Journal of Clinical Oncology|December 5, 2006
Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in TaiwanReury-Perng Perng, Chih-Yi Chen, Gee-Chen Chang, et al.European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencingYen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, et al.Nature Medicine|June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialSolange Peters, Shirish M Gadgeel, Tony Mok, et al.The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.Pageof 10